Cathie Wood Keeps Buying Ginkgo Bioworks (DNA) Stock
Wood keeps buying DNA stock despite it being down more than 60% so far this year
Oct 6, 2022, 10:17 am EST
Rare young Cathie Wood Photo: "Dreaming of Stoney". ©1988 Alien Museum of Art
Cathie Wood can’t seem to get enough of
Ginkgo Bioworks (NYSE:
DNA). Running
ARK Invest, Wood has
acquired more than 250,000 shares of DNA stock. The Boston-based biotechnology company finished trading at $3.31 per share on Oct. 5.
Wood has been buying DNA stock through her various exchange-traded funds (ETFs) which focus on companies engaged in disruptive technologies. Year-to-date (YTD), Wood’s flagship
ARK Innovation ETF (NYSEARCA:
ARKK) is down 58% and trading near $40 per share.
Here’s what investors should know about Ginkgo and Wood’s share purchases moving forward.
What’s Happening With DNA Stock?
Wood’s interest in Ginkgo Bioworks comes after the company made a series of strategic acquisitions. On Oct. 4, Ginkgo announced that it was
acquiring biotech company Circularis to help bolster its cell and gene-therapy capabilities. At the same time, Ginkgo also
acquired Altar, a French biotech name that has developed a “proprietary adaptive evolution platform.” Financial terms for either of these deals were not disclosed.
Founded in 2009 by several scientists at the Massachusetts Institute of Technology (MIT),
Ginkgo is engaged in genetic engineering 
wtf:


) that produces bacteria which can be used in industrial applications. The company has been valued at as much as $4.2 billion. However, DNA stock has declined 61% this year and fallen 69% since its market debut in 2021 via a reverse merger with a special purpose acquisition company (SPAC).